These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
162 related articles for article (PubMed ID: 16907906)
1. Presence of plasma complement regulatory proteins clusterin (Apo J) and vitronectin (S40) on circulating immune complexes (CIC). Chauhan AK; Moore TL Clin Exp Immunol; 2006 Sep; 145(3):398-406. PubMed ID: 16907906 [TBL] [Abstract][Full Text] [Related]
2. Determination of circulating immune complexes, C3 and C4 complement components and anti-DNA antibody in different classes of lupus nephritis. Klein MH; Thorner PS; Yoon SJ; Poucell S; Baumal R Int J Pediatr Nephrol; 1984 Jun; 5(2):75-82. PubMed ID: 6333404 [TBL] [Abstract][Full Text] [Related]
4. Cloning of the sixth complement component and, spatial and temporal expression profile of MAC structural and regulatory genes in chicken. Mikrou A; Zarkadis IK Dev Comp Immunol; 2010 May; 34(5):485-90. PubMed ID: 20067805 [TBL] [Abstract][Full Text] [Related]
5. Circulating immune complex levels measured by new ELISA kits utilizing monoclonal anti-C1q and anti-C3d antibodies correlate with clinical activities of SLE but not with those of RA. Yoshinoya S; Mizoguchi Y; Aotsuka S; Yokohari R; Nishioka K; Miyamoto T J Clin Lab Immunol; 1992; 38(4):161-73. PubMed ID: 11270517 [TBL] [Abstract][Full Text] [Related]
6. Significance of complement components C1q and C4 bound to circulating immune complexes in juvenile idiopathic arthritis: support for classical complement pathway activation. Gilliam BE; Reed MR; Chauhan AK; Dehlendorf AB; Moore TL Clin Exp Rheumatol; 2011; 29(6):1049-56. PubMed ID: 22153664 [TBL] [Abstract][Full Text] [Related]
7. Correlation of C3d fixing circulating immune complexes with disease activity and clinical parameters in patients with systemic lupus erythematosus. Sekita K; Doi T; Muso E; Yoshida H; Kanatsu K; Hamashima Y Clin Exp Immunol; 1984 Mar; 55(3):487-94. PubMed ID: 6608422 [TBL] [Abstract][Full Text] [Related]
8. Circulating immune complexes in lupus erythematosus, scleroderma and dermatomyositis. Sølling J; Sølling K; Jacobsen KU Acta Derm Venereol; 1979; 59(5):421-6. PubMed ID: 93365 [TBL] [Abstract][Full Text] [Related]
9. Relationship between anti-DNA antibodies complement consumption and circulating immune complexes in systemic lupus erythematosus. Davis P; Cumming RH; Verrier-Jones J Clin Exp Immunol; 1977 May; 28(2):226-32. PubMed ID: 301447 [TBL] [Abstract][Full Text] [Related]
10. The complement fixing ability of putative circulating immune complexes in rheumatoid arthritis and its relationship to extra-articular disease. Bourke BE; Moss IK; Mumford P; Horsfall A; Maini RN Clin Exp Immunol; 1982 Jun; 48(3):726-32. PubMed ID: 6981475 [TBL] [Abstract][Full Text] [Related]
11. An enzyme-linked immunoassay for detection of IgG- and C3-containing circulating immune complexes: comparison with a radioimmunoassay and quantitation in patients with rheumatic diseases. Panush RS; Somberg LB; Katz P; Longley S Diagn Immunol; 1983; 1(4):288-94. PubMed ID: 6388973 [TBL] [Abstract][Full Text] [Related]
12. Clinical management of patients with systemic lupus erythematosus (SLE) with different C1q-CIC and C3 concentrations. Karamehic J; Subasic D; Kasumovic M; Hodzic H; Prljaca-Zecevici L; Tufekcic M; Aganovic-Musinovic I Med Arh; 2010; 64(2):75-9. PubMed ID: 20514769 [TBL] [Abstract][Full Text] [Related]
13. Membrane attack complex (MAC) deposits in skin are not always accompanied by S-protein and clusterin. French LE; Polla LL; Tschopp J; Schifferli JA J Invest Dermatol; 1992 May; 98(5):758-63. PubMed ID: 1569324 [TBL] [Abstract][Full Text] [Related]
14. Soluble MAC is primarily released from MAC-resistant bacteria that potently convert complement component C5. Doorduijn DJ; Lukassen MV; van 't Wout MFL; Franc V; Ruyken M; Bardoel BW; Heck AJR; Rooijakkers SHM Elife; 2022 Aug; 11():. PubMed ID: 35947526 [TBL] [Abstract][Full Text] [Related]
15. Correlations of C1q- and C3d-bearing circulating immune complexes with immunopathological disease activity in lupus nephritis patients. Muso E; Yashiro M; Ito Y; Yoshida H; Sasayama S Nihon Jinzo Gakkai Shi; 1994 Apr; 36(4):345-54. PubMed ID: 8022107 [TBL] [Abstract][Full Text] [Related]
16. Terminal complement complex in plasma from patients with systemic lupus erythematosus and other glomerular diseases. Horigome I; Seino J; Sudo K; Kinoshita Y; Saito T; Yoshinaga K Clin Exp Immunol; 1987 Nov; 70(2):417-24. PubMed ID: 3427827 [TBL] [Abstract][Full Text] [Related]
17. Supported Lipid Bilayer Platform To Test Inhibitors of the Membrane Attack Complex: Insights into Biomacromolecular Assembly and Regulation. Yorulmaz S; Jackman JA; Hunziker W; Cho NJ Biomacromolecules; 2015 Nov; 16(11):3594-602. PubMed ID: 26444518 [TBL] [Abstract][Full Text] [Related]
18. Binding of complement component C5 to model immune complexes and the use of anti-C5 antibodies for determination of C5-containing circulating immune complexes. Larsson A; Sjöquist J J Clin Lab Immunol; 1989 Jan; 28(1):5-9. PubMed ID: 2724329 [TBL] [Abstract][Full Text] [Related]
19. [Complement components, whole complement activity, and circulating immune complexes in neoplastic diseases]. Takada K; Morishita M; Sugiura T; Suzuki M; Torii Y; Ichimura K; Hashigami H; Toshikawa K; Ina Y; Yamamoto M; Oyama A; Urata A Gan No Rinsho; 1983 Apr; 29(4):A-19, 293-6. PubMed ID: 6602233 [TBL] [Abstract][Full Text] [Related]
20. Clusterin in renal tissue: preferential localization with the terminal complement complex and immunoglobulin deposits in glomeruli. French LE; Tschopp J; Schifferli JA Clin Exp Immunol; 1992 Jun; 88(3):389-93. PubMed ID: 1606720 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]